Acaluxen is presented on this website as a product containing 100 mg of acalabrutinib.
Product identity
| Product characteristic | Information |
|---|---|
| Product | Acaluxen |
| Active ingredient | Acalabrutinib |
| Stated strength | 100 mg |
| Drug class | Bruton tyrosine kinase inhibitor |
| Therapeutic category | Antineoplastic |
| Route | Oral, subject to product documentation |
| Reference product | CALQUENCE |
| Acaluxen manufacturer | Everest Pharmaceuticals Ltd. |
| Acaluxen authorization | leukemia |
Acalabrutinib inhibits BTK, an important component of B-cell receptor signaling. This mechanism underlies its activity in selected B-cell malignancies.
Medical uses
Current U.S. CALQUENCE labeling covers adult CLL/SLL and specified MCL settings. European authorization includes additional treatment combinations in specified CLL and MCL populations.
Reference product
CALQUENCE is the established reference brand for acalabrutinib. Acalabrutinib was developed by Acerta Pharma, followed by AstraZeneca’s majority investment and subsequent development activities.
Safety
Important risks of acalabrutinib include serious infections, bleeding, cytopenias, second primary malignancies, cardiac arrhythmias and hepatotoxicity.
Product verification
The actual package, manufacturer and applicable authorization documentation should be checked before use. No Acaluxen-specific authentication system should be claimed without primary evidence.